spacer
home > > autumn 2003 > driving patient compliance
PUBLICATIONS


Driving Patient Compliance

The Scope of the Problem

Non-compliance commonly refers to the failure of patients to take medicines in their prescribed manner. Recognised as a serious health care issue, studies show that patient non-compliance can range from 20-80 per cent depending on the type of treatment being taken (1). The problem of non-compliance is not a new one and has been investigated for several decades worldwide.

The Consequences

Patient non-compliance lessens the quality of health care and can lead to dangerous consequences for patients. In the US, it has been estimated that non-compliance causes 340 deaths per day and is responsible for 10-25 per cent of hospital and nursing home admissions. Patient non-compliance is taken so seriously in the US that the New York Times dubbed it the nation's 'other drug problem' (2).

In a recent study conducted by Dendrite's Analytika Division, based on an analysis of data from nearly half of the US retail chain and independent companies, it was discovered that 'fewer than one in four patients on a cholesterol-lowering therapy completes a full year of treatment' (3). For the pharma industry, this gap between compliance and persistence translates into vast amounts of lost revenue.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc

Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.


Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.


spacer
Pietro Bonacossa
spacer
spacer
spacer
Dr Faiz Kermani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement